Literature DB >> 26604278

How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins.

Francesca Porcellati1, Paola Lucidi1, Geremia B Bolli2, Carmine G Fanelli1.   

Abstract

Entities:  

Year:  2015        PMID: 26604278     DOI: 10.2337/dc15-1848

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  6 in total

1.  Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL-1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus.

Authors:  Tim Heise; Charles Donnelly; Abhijit Barve; Patrick Aubonnet
Journal:  Diabetes Obes Metab       Date:  2019-12-15       Impact factor: 6.577

2.  Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study.

Authors:  Yi Tao; Mingxue Zhu; Junliang Pu; Peilin Zhang; Lei Wan; Chengyong Tang
Journal:  Front Pharmacol       Date:  2021-12-02       Impact factor: 5.810

3.  How to Achieve Sufficient Endogenous Insulin Suppression in Euglycemic Clamps Assessing the Pharmacokinetics and Pharmacodynamics of Long-Acting Insulin Preparations Employing Healthy Volunteers.

Authors:  Hui Liu; Ting Li; Hongling Yu; Jiaqi Li; Huiwen Tan; Yerong Yu
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

4.  Effects of Unsuppressed Endogenous Insulin on Pharmacokinetics and/or Pharmacodynamics of Study Insulin in the Healthy: A Retrospective Study.

Authors:  Hui Liu; Hongling Yu; Lisi Sun; Jingtao Qiao; Jiaqi Li; Huiwen Tan; Yerong Yu
Journal:  Clin Pharmacol Drug Dev       Date:  2022-04-05

5.  Insulin's Role in Diabetes Management: After 90 Years, Still Considered the Essential "Black Dress".

Authors:  William T Cefalu; Julio Rosenstock; Derek LeRoith; Matthew C Riddle
Journal:  Diabetes Care       Date:  2015-12       Impact factor: 19.112

6.  Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.

Authors:  Ulrich Werner; Norbert Tennagels; Carmine G Fanelli; Geremia B Bolli
Journal:  Diabetes Obes Metab       Date:  2020-10-19       Impact factor: 6.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.